First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo
Mingming Wei, Rui Zhao, Yuting Cao, Yujiao Wei, Ming Li, Zhiqiang Dong, Yulin Liu, Hao Ruan, Ying Li, Sheng Cao, Zhiwen Tang, Yuanyuan Zhou, Wei Song, Yubo Wang, Jiefu Wang, Guang Yang, Cheng Yang
Topics & Concepts
ProdrugChemistryCyclin-dependent kinaseBioavailabilityKinaseIn vivoPharmacologyProteolysisCDK inhibitorBiochemistryCancer researchApoptosisCell cycleEnzymeBiologyBiotechnologyProtein Degradation and InhibitorsAdvanced Breast Cancer TherapiesMultiple Myeloma Research and Treatments